Display options
Share it on

Sci Pharm. 2017 Feb 27;85(1). doi: 10.3390/scipharm85010008.

Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application.

Scientia pharmaceutica

Tomi Hendrayana, André Wilmer, Verena Kurth, Ingo Gh Schmidt-Wolf, Ulrich Jaehde

Affiliations

  1. Institute of Pharmacy, Clinical Pharmacy, University of Bonn, D-53121 Bonn, Germany. [email protected].
  2. School of Pharmacy, Institut Teknologi Bandung (ITB), Bandung 40132, Indonesia. [email protected].
  3. Institute of Pharmacy, Clinical Pharmacy, University of Bonn, D-53121 Bonn, Germany. [email protected].
  4. Institute of Pharmacy, Clinical Pharmacy, University of Bonn, D-53121 Bonn, Germany. [email protected].
  5. Med. Klinik III und Poliklinik, Center for Integrated Oncology (CIO), University of Bonn, D-53127 Bonn, Germany. [email protected].
  6. Institute of Pharmacy, Clinical Pharmacy, University of Bonn, D-53121 Bonn, Germany. [email protected].

PMID: 28264440 PMCID: PMC5388145 DOI: 10.3390/scipharm85010008

Abstract

Most anticancer agents exhibit a narrow therapeutic index, i.e., a small change in plasma concentrations can lead to a less efficacious treatment or an unacceptable degree of toxicity. This study aimed at providing health professionals with a feasible and time-saving tool to adapt the dose of anticancer agents for patients with renal or hepatic dysfunction. A guideline for anticancer agents was developed based on a literature search. An algorithm was generated to enhance the efficiency of the dose adaptation process. Finally, the dosing guideline was converted into an easy-to-use Excel

Keywords: anticancer; dose adjustment; hepatic dysfunction; renal dysfunction

References

  1. Lung. 2009 Jan-Feb;187(1):69-74 - PubMed
  2. Clin Pharmacokinet. 1997 Apr;32(4):324-43 - PubMed
  3. Crit Rev Oncol Hematol. 2012 Jan;81(1):58-74 - PubMed
  4. Med Sci Monit. 2004 May;10(5):CR209-12 - PubMed
  5. Lancet Oncol. 2008 Nov;9(11):1092-101 - PubMed
  6. Br J Cancer. 2002 Apr 22;86(8):1297-302 - PubMed
  7. Oncologist. 2007 Sep;12(9):1070-83 - PubMed
  8. Ann Intern Med. 1999 Mar 16;130(6):461-70 - PubMed
  9. Oncologist. 2007 Feb;12(2):152-5 - PubMed
  10. Br J Clin Pharmacol. 1997 Sep;44(3):261-5 - PubMed
  11. Oncology (Williston Park). 2005 Jul;19(8):1057-63; discussion 1063-4, 1069 - PubMed
  12. Crit Rev Oncol Hematol. 2009 May;70(2):124-33 - PubMed
  13. Cancer Treat Rev. 1995 Jan;21(1):33-64 - PubMed
  14. J Am Soc Nephrol. 2002 Aug;13(8):2140-4 - PubMed
  15. Clin Chem. 1998 Feb;44(2):388-400 - PubMed
  16. Nephron. 1976;16(1):31-41 - PubMed
  17. J Clin Oncol. 2006 Feb 1;24(4):533-6 - PubMed
  18. Clin Oncol (R Coll Radiol). 2007 Mar;19(2):99-107 - PubMed
  19. Br J Cancer. 2008 Feb 12;98(3):517-22 - PubMed
  20. Eur J Cancer. 2007 Jan;43(1):14-34 - PubMed
  21. Br J Cancer. 2010 Dec 7;103(12):1815-21 - PubMed
  22. Lancet Oncol. 2008 Dec;9(12):1181-90 - PubMed
  23. Int J Gynecol Cancer. 2007 Jul-Aug;17(4):739-63 - PubMed

Publication Types